Abstract
Respiratory syncytial virus (RSV) is worldwide a very important virus leading to infection of the respiratory system. In particular preterm babies, infants and elderly adults are prone to developing severe diseases such as bronchiolitis or pneumonia, which require intensive care and cause increased mortality. Although RSV is rapidly detected, preventive and therapeutic measures are limited. New antivirals are already in clinical trials.
Keywords:
Antiviral agents; Bronchiolitis; Pneumonia; Respiratory syncytial virus infections; Risk factors.
MeSH terms
-
Adult
-
Aged
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / therapeutic use
-
Bronchiolitis / diagnosis*
-
Bronchiolitis / drug therapy
-
Bronchiolitis / prevention & control*
-
Bronchiolitis / virology
-
Bronchiolitis, Viral / diagnosis
-
Bronchiolitis, Viral / virology
-
Humans
-
Infant
-
Infant, Newborn
-
Pneumonia / diagnosis
-
Pneumonia / virology
-
Respiratory Syncytial Virus Infections / diagnosis*
-
Respiratory Syncytial Virus Infections / drug therapy
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Infections / virology
-
Respiratory Syncytial Virus, Human / immunology
-
Respiratory Syncytial Virus, Human / isolation & purification*
-
Risk Factors